Optimal allocation of testing dollars: The example of HIV counseling, testing, and referral

Medical Decision Making

Volumn 25, Issue 3, 2005, Pages 321-329

  Walensky, Rochelle P ^a,d   Weinstein, Milton C ^b   Smith, Heather E ^a   Freedberg, Kenneth A ^a,b   Paltiel, A David ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD CENTER FOR RISK ANALYSIS   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Division of General Medicine   (United States)

Author keywords

Cost effectiveness; HIV; Linkage; Screening test

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MASS SCREENING; OPPORTUNISTIC INFECTION; PATIENT COUNSELING; PATIENT REFERRAL; PREVALENCE; PROBABILITY; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; SIDE EFFECT; SIMULATION;

AIDS SERODIAGNOSIS; COMPUTER SIMULATION; CONTINUITY OF PATIENT CARE; COST-BENEFIT ANALYSIS; COUNSELING; DECISION SUPPORT TECHNIQUES; HIV INFECTIONS; HUMANS; INVESTMENTS; MASS SCREENING; MODELS, STATISTICAL; PATIENT ACCEPTANCE OF HEALTH CARE; PREVALENCE; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; REFERRAL AND CONSULTATION; RESOURCE ALLOCATION; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 18844378093     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X05276955     Document Type: Article

References (42)

1. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, Second Edition: Report of the Clinical Preventive Services Task Force. Washington, DC: US Department of Health and Human Services. Office of Public Health and Science. Office of Disease Prevention and Health Promotion; 1996.
2. Walensky RP, Losina E, Malatesta L, et al. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health. 2005;95(1):71-73.
3. Valdiserri RO, Moore M, Gerber AR, et al. A study of clients returning for counseling after HIV testing: implications for improving rates of return. Public Health Rep. 1993;108(1):12-18.
4. Bell RA, Truax SR, Ruiz PD, Sun RK, Molitor F. Predictors of failure to return for HIV test result and counseling by test site type. AIDS Educ Prev. 1999;11(1):1-13.
5. Tao G, Branson BM, Kassler WJ, Cohen RA. Rates of receiving HIV test results: data from the U.S. National Health Interview Survey for 1994 and 1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;22(4):395-400.
6. Centers for Disease Control and Prevention. HIV Counseling and Testing in Publicly Funded Sites: 1995 Summary Report. Atlanta, GA: US Department of Health and Human Services; 1997.
7. Routinely recommended HIV testing at an urban urgent-care clinic - Atlanta, Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(25):538-41.
8. Advancing HIV prevention: new strategies for a changing epidemic - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(15):329-32.
9. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-60.
10. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-31.
11. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy, clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-50.
12. Paltiel AD, Goldie SJ, Losina E, et al. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001;32(5): 783-93.
13. Walensky RP, Goldie SJ, Sax PE, et al. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002;31(1):27-37.
14. Freedberg KA, Scharfstein JA, Seage GR 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2):130-6.
15. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Available from: http://www.hivatis.org/guidelines/ adult/May23_02/ AAMay23.pdf. Accessed August 15, 2002.
16. 2001 USPHS/DDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV. November 28, 2001. Available from: http://www.hivatis.org/trtgdlns.html#Opportunistic. Accessed December 21, 2001.
17. Spielberg F, Jackson S. Modeling HIV testing with the OraQuick finger-stick test: more effective and less costly than oral fluid testing at bathhouses and a needle exchange [abstract M2-C1701]. Paper presented at 2003 National HIV Prevention Conference, July 2 7-30,2003, Atlanta, GA.
18. Ekwueme DU, Pinkerton SD, Holtgrave DR, Branson BM. Cost comparison of three HIV counseling and testing technologies. Am J Prev Med. 2003;25(2):112-21.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
20. Walensky RP, Weinstein MC, Kimmel AD, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005;118(3):292-300.
21. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586-595.
22. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946-54.
23. Statistical Abstract of the United States: 1998. 118th edition. Washington, DC: Bureau of the Census; 1998.
24. Mylonakis E. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med. 2000;109:568-76.
25. Varghese B, Peterman TA, Holtgrave DR. Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS. 1999;13(13):1745-51.
26. Farnham PG, Gorsky RD, Holtgrave DR, Jones WK, Guinan ME. Counseling and testing for HIV prevention: costs, effects, and cost-effectiveness of more rapid screening tests. Public Health Rep. 1996;111(1):44-53.
27. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release PO4. Springfield, VA: National Technical Information Service; 1995.
28. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-73.
29. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-733.
30. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;12(9):F83-93.
31. Drug Topics Red Book. Montvale, NJ: Medical Economics; 2001.
32. HIV counseling and testing in publicly funded sites: 1995 summary report. Atlanta: US Department of Health and Human Services. Centers for Disease Control and Prevention; September 1997.
33. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS. 2001;15(1):77-85.
34. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339(26):1897-904.
35. Yee D. AIDS activists "frustrated" with CDC's new HIV prevention efforts. Associated Press. July 29, 2003.
36. Leff L. CDC's new HIV prevention plan faces criticism. Associated Press. July 27, 2003.
37. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-41.
38. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep. 2001;50(RR-19):1-57.
39. OraSure receives FDA approval for OraQuick Rapid HIV-1 Test. Business Wire. Available from: http://www.aegis.com/news//bw/ 2002/BW021104.html. Accessed August 15, 2003.
40. Kroc K, Papiez G, Parks D, et al. Routine screening of emergency department (ED) patients using OraQuick HIV-1 antibody test. Paper presented at CDC HIV Prevention Conference, July 27-30, 2003, Atlanta, GA.
41. Keenan P. HIV outreach in the African American community using OraQuick rapid testing. Paper presented at CDC HIV Prevention Conference, July 27-30, 2003, Atlanta, GA.
42. Nichols A, Weinstein MC. Optimal resource allocation in community hypertension programs. Manage Sci. 1978;24(14):1526-37.